PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR PRIMARY HYPEROXALURIA TYPE

被引：0
|
作者：
Habtemariam, B. [1 ]
Attarwala, H. [1 ]
Cao, K. [1 ]
Clausen, V. [1 ]
Goel, V. [1 ]
Melch, M. [1 ]
McGregor, T. L. [1 ]
Robbie, G. J. [1 ]
机构：
[1] Alnylam Pharmaceut, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
LB-019
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [21] Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males
    Aldabek, Khaled
    Grossman, Oulimata K.
    AL-Omar, Osama
    Fox, Janelle A.
    Moritz, Michael L.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [22] Lumasiran for primary hyperoxaluria type 1: What we have learned?
    Gang, Xuan
    Liu, Fei
    Mao, Jianhua
    FRONTIERS IN PEDIATRICS, 2023, 10
  • [23] Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1
    Hulton, Sally-Anne
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (7-10): : 189 - 198
  • [24] A Phase 1/2 Trial of ALN-GO1, an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1 (PH1)
    Hulton, S-A.
    Frishberg, Y.
    Milliner, D.
    Hoppe, B.
    Lorch, U.
    Olgesbee, D.
    Lieske, J.
    Haslett, P.
    PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1763 - 1763
  • [25] Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
    Hulton, Sally A.
    Groothoff, Jaap W.
    Frishberg, Yaacov
    Koren, Michael J.
    Overcash, J. Scott
    Sellier-Leclerc, Anne-Laure
    Shasha-Lavsky, Hadas
    Saland, Jeffrey M.
    Hayes, Wesley
    Magen, Daniella
    Moochhala, Shabbir H.
    Coenen, Martin
    Simkova, Eva
    Garrelfs, Sander F.
    Sas, David J.
    Meliambro, Kristin A.
    Ngo, Taylor
    Sweetser, Marianne T.
    Habtemariam, Bahru A.
    Gansner, John M.
    McGregor, Tracy L.
    Lieske, John C.
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (03): : 494 - 506
  • [26] Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 : Results from a Phase III Clinical Trial
    Saland, Jeffrey M.
    Lieske, John C.
    Groothoff, Jaap W.
    Frishberg, Yaacov
    Shasha-Lavsky, Hadas
    Magen, Daniella
    Moochhala, Shabbir H.
    Simkova, Eva
    Coenen, Martin
    Hayes, Wesley
    Hogan, Julien
    Sellier-Leclerc, Anne-Laure
    Willey, Richard
    Gansner, John M.
    Hulton, Sally -Anne
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2037 - 2046
  • [27] DEVELOPMENT OF AN RNAI THERAPEUTIC TARGETING GLYCOLATE OXIDASE FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1
    Liebow, Abigail
    Erbe, David
    Li, Xingsheng
    Fargue, Sonia
    Milstein, Stuart
    Kuchimanchi, Satya
    Fitzgerald, Kevin
    Querbes, William
    Holmes, Ross
    Knight, John
    Meyers, Rachel
    PEDIATRIC NEPHROLOGY, 2015, 30 (09) : 1564 - 1564
  • [28] Re: An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria Editorial Comment
    Assimos, Dean G.
    JOURNAL OF UROLOGY, 2017, 197 (05): : 1297 - 1298
  • [29] Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1
    Saffe, Sina
    Doerry, Katja
    Buscher, Anja K.
    Hansen, Matthias
    Rohmann, Melanie
    Kanzelmeyer, Nele
    Latta, Kay
    Kemper, Markus J.
    Loos, Sebastian
    PEDIATRIC NEPHROLOGY, 2025,
  • [30] Lumasiran in the Management of Patients with Primary Hyperoxaluria Type I: From Bench to Bedside
    D'Ambrosio, Viola
    Ferraro, Pietro Manuel
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2022, 15 : 197 - 206
12345